Gonadorelin 2mg

Gonadorelin (GnRH) is a decapeptide agonist of gonadotropin-releasing hormone. It promotes the production and release of luteinizing hormone and follicle-stimulating hormone. In human medicine, it is utilized to address infertility, irregularities in the menstrual cycle, and hypogonadism. Additionally, it serves as a diagnostic tool for evaluating pituitary function. Current research indicates potential applications for gonadorelin in the treatment of breast and prostate cancers as well as Alzheimer's disease.

Studies suggest that higher lifetime estrogen exposure may elevate a woman's risk of developing breast cancer. Women who begin menstruating at a younger age, experience menopause later, use estrogen-containing contraceptives, or undergo hormone replacement therapy during menopause are at greater risk for breast cancer. Fortunately, the risk associated with contraceptive use diminishes after stopping the pills and eventually reverts to baseline levels. Birth control, however, presents a dual risk as, while it increases the risk of breast cancer, it simultaneously lowers the risk of ovarian cancer.
Certain breast cancer cells require estrogen for growth, and reducing estrogen production or blocking its receptors has been a well-established approach to treating particular types of breast cancer. Research into gonadorelin indicates its potential to inhibit ovarian estrogen production, which may help in breast cancer prevention. This approach is founded on the premise that some women, influenced by genetic and environmental factors, face a heightened risk of breast cancer after menopause. Utilizing gonadorelin in this context is both safe and cost-effective, thus making it a promising strategy for minimizing cancer risk. Studies propose that a decade-long use of gonadorelin could lower breast cancer risk by as much as 50%, and a 15-year use could cut the risk by 70%.

The advantages of gonadorelin extend beyond merely preventing breast cancer. Research shows that adjuvant therapies with anti-estrogens can reduce disease progression by up to 50% in estrogen-sensitive cancer cases. Unfortunately, existing treatments often fall short due to cancer cells developing resistance over time, typically due to heightened expression of estrogen receptors, which makes it challenging to block all receptors without causing severe side effects. Gonadorelin may address this issue by reducing estrogen expression initially. This would not only directly inhibit the growth of estrogen-sensitive cancers but also enhance the effectiveness of receptor-blocking therapies and prolong their efficacy.

Studies in postmenopausal women experiencing hyperandrogenism (excess estrogen) have found that long-term GnRH treatment lowers overall estrogen levels and, consequently, the risk of breast cancer. Importantly, it achieves this without significant side effects, providing a viable alternative to the current treatment method, which involves surgical ovary removal.

Research demonstrates that sex hormones, especially luteinizing hormone (LH), influence the brain in ways that extend far beyond sexual dimorphism or reproductive functions. Notably, the rise in LH associated with menopause has been linked to an increased incidence of Alzheimer’s disease and a decline in memory performance in humans.